The SPAC Makes a Comeback!
When the people are the sole assets.
Leadership and Industry Image
A recent roundtable moderated by Rob Jekielek of The Harris Poll gathered five biopharma CEOs to discuss the industry’s shifting reputational landscape in the public eye.
Assets in Anxious Times: Patient Hubs Demonstrate Value During COVID-19
How ramped-up support and educational services have helped bridge the chasms and ease fears along the patient care continuum.
The Interplay Between COVID-19 Pandemic and NCD Epidemic
Amid attention on coronavirus, efforts to address the burden of non-communicable diseases are at a critical juncture.
FDA Struggles to Retain Credibility
Missteps threaten agency’s independence as vaccines seek finish line.
Critical Connection: Patient Services and Product Launch
A look at best-practice approaches to aligning the strategy and design of hub service models with preparations for market entry of a new therapy.
Mastering the Transition From Academia to Industry
Tips for rounding out the rough edges in crossover.
Smoothing Access Path
The role of advanced data technologies in reducing hurdles.
The COVID Boost to AI in Global Health
Report sets out self-assessment measures for low- and middle-income countries in their adoption of new health technologies.
Pharmaceutical Executive, October 2020 Issue (PDF)
Click the title above for a link to open the Pharmaceutical Executive October 2020 issue in an interactive PDF format.
Speed and Sensitivity
Anne E. White, president, Lilly Oncology, talks about how the lessons she learned from leading a startup helped her to speed Lilly’s drug development from target identification through successful launch
New Views Point the Way
Previewing executive trends thought of by leaders in the pharma industry.
The Shifting Kaleidoscope of EU Pharma Policy
Universal strategy push elicits range of constituency views.
The Regulatory Engagement Conundrum
Biopharma must find sustainable models for public policy engagement.
